CYTOSORBENTS CORPORATION Depreciation
CYTOSORBENTS CORPORATION (CTSO) reported Depreciation of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- CYTOSORBENTS CORPORATION depreciation for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- CYTOSORBENTS CORPORATION depreciation for the quarter ending 2026-03-31 was $289.00K, a 5.56% decline year-over-year.
- CYTOSORBENTS CORPORATION depreciation for the quarter ending 2025-12-31 was $300.00K, a 0.00% change year-over-year.
- CYTOSORBENTS CORPORATION depreciation for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- CYTOSORBENTS CORPORATION depreciation for fiscal 2025 was $1.20M, a 7.69% decline from fiscal 2024.
- CYTOSORBENTS CORPORATION depreciation for fiscal 2024 was $1.30M, a 4.87% increase from fiscal 2023.
- CYTOSORBENTS CORPORATION depreciation for fiscal 2023 was $1.24M, a 80.03% increase from fiscal 2022.
- CYTOSORBENTS CORPORATION depreciation for fiscal 2022 was $688.57K, a 20.56% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed | Depreciation 191 month | Depreciation 203 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $889.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $289.00K 10-Q · filed 2026-05-13 | $589.00K derived: sum of 2 quarters · filed 2026-05-13 | $889.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $600.00K derived: sum of 2 quarters · filed 2026-03-30 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-13 | $600.00K derived: sum of 2 quarters · filed 2026-08-06 | $900.00K 10-Q · filed 2025-11-13 | $1.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $906.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $306.00K 10-Q · filed 2026-05-13 | $305.70K 10-Q · filed 2025-05-14 | $606.00K derived: sum of 2 quarters · filed 2026-05-13 | $906.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.36M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $600.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.06M derived: sum of 3 quarters · filed 2026-03-30 | $1.30M 10-K · filed 2026-03-30 | $1.34M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-13 | $757.80K derived: sum of 2 quarters · filed 2025-11-13 | $1.00M 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | $457.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $800.00K 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | $342.20K 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | $1.24M 10-K · filed 2025-03-31 | |||||||
| 2022-12-31 | $688.57K 10-K · filed 2024-03-15 | |||||||
| 2021-12-31 | $571.16K 10-K · filed 2024-03-15 | $542.69K 10-K · filed 2022-03-10 | ||||||
| 2020-12-31 | $553.95K 10-K · filed 2023-03-09 | |||||||
| 2019-12-31 | $495.73K 10-K · filed 2022-03-10 | |||||||
| 2018-12-31 | $329.47K 10-K · filed 2021-03-09 | |||||||
| 2017-12-31 | $177.78K 10-K · filed 2020-03-05 | |||||||
| 2016-12-31 | $126.11K 10-K · filed 2019-03-07 | |||||||
| 2015-12-31 | $87.40K 10-K · filed 2018-03-08 | $87.40K 10-K · filed 2016-03-09 | ||||||
| 2014-12-31 | $48.43K 10-K · filed 2017-03-03 | |||||||
| 2013-12-31 | $39.89K 10-K · filed 2015-03-31 | $2.46M 10-K · filed 2014-03-31 | ||||||
| 2012-12-31 | $29.32K 10-K · filed 2014-03-31 | $2.40M 10-K · filed 2013-04-03 | ||||||
| 2011-12-31 | $23.75K 10-K · filed 2013-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |